UBS analyst Thomas Wadewitz raised the firm’s price target on RXO Inc. (RXO) to $17 from $15 and keeps a Neutral rating on the shares. The company pointed to a further decline in Q1 EBITDA, creating a difficult setup for the stock, the analyst tells investors in a research note. UBS cites more optimism on a cycle turn for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO:
- Balanced Hold on RXO: Near-Term Earnings Pressure vs. Emerging Truckload Recovery Upside
- Balancing Near-Term Weakness and AI-Driven Upside: Why RXO Merits a Buy Rating
- RXO Establishes New Credit Facility Amid Weaker Earnings
- RXO Inc. reports Q4 adjusted EPS (7c), consensus (4c)
- RXO Inc. sees Q1 adjusted EBITDA $5M-$12M